"Niacinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
| Descriptor ID |
D009536
|
| MeSH Number(s) |
D03.066.515.530 D03.383.725.547.530
|
| Concept/Terms |
Niacinamide- Niacinamide
- Vitamin B 3
- B 3, Vitamin
- 3-Pyridinecarboxamide
- 3 Pyridinecarboxamide
- Vitamin B3
- B3, Vitamin
- Nicotinamide
- Vitamin PP
|
Below are MeSH descriptors whose meaning is more general than "Niacinamide".
Below are MeSH descriptors whose meaning is more specific than "Niacinamide".
This graph shows the total number of publications written about "Niacinamide" by people in this website by year, and whether "Niacinamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Decreased risk of cardiovascular disease in dermatology patients taking niacinamide: A TriNetX cohort study. J Am Acad Dermatol. 2026 Mar; 94(3):828-834.
-
Immature Acta2R179C/+ smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS. Nat Commun. 2025 Jul 02; 16(1):6105.
-
Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers. Respir Res. 2023 Nov 04; 24(1):265.
-
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 06 01; 22(6):717-725.
-
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis. Future Microbiol. 2022 Oct; 17:1217-1229.
-
SIRT3 is required for liver regeneration but not for the beneficial effect of nicotinamide riboside. JCI Insight. 2021 04 08; 6(7).
-
Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib. Int J Pharm. 2018 May 05; 542(1-2):196-204.
-
The treatment path in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 9(8):1-20.
-
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4780-4792.
-
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.